The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free

Recruiting now · Phase 4

Conditions studied: Dry Eye Disease (DED)

In brief

The goal of this investigational study is to determine if Systane PRO Preservative Free is non-inferior to BLINK TRIPLE CARE in the clinically significant improvement of signs and symptoms of dry eye in patients over 4 weeks.

Key facts

Study ID

NCT07745062

Run by

Gordon Schanzlin New Vision

People needed

30

Starts

2026-07-17

Expected to finish

2027-04-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: Adults ≥ 18 years.
• Diagnosis: Clinical diagnosis of mild to moderate dry eye disease in at least one eye with OSDI ≥ 13 to ≤ 32 at screening.
• OSDI ≥ 13 to ≤ 32 at screening.
• Objective evidence: NITBUT ≤ 10 seconds in the study eye(s) at screening.
• Ocular surface status: CFS ≤ grade 3 (Oxford or NEI scale) in the study eye(s).
• Stable medications: Systemic medications that may affect tear film must be stable ≥ 30 days prior to screening and expected to remain stable during the study.
• Ability to participate: Able and willing to comply with procedures, attend visits, and provide written informed consent.
• Contraception: Women of childbearing potential must agree to use an acceptable method of contraception for the study duration and have a negative pregnancy test at screening.

You may not qualify if…

• Active ocular infection or inflammation unrelated to DED (e.g., bacterial/viral conjunctivitis, active uveitis).
• Severe ocular surface disease beyond typical DED (e.g., severe keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid).
• Excessive corneal staining: CFS > grade 3 in the study eye(s).
• Recent ocular surgery or procedure: ocular surgery, laser, or punctal occlusion within 6 months prior to screening.
• Current or prior use within 6 months before screening of either study drop (Systane PRO PF or Blink Triple Care PF)
• Contact lens wear: soft or rigid contact lens use within 7 days prior to baseline, or unwillingness to discontinue lenses for the study; consider extending to 14 days if desired.
• Use of topical ophthalmic medications that cannot be discontinued (e.g., topical antibiotics, corticosteroids).
• Recent investigational product use: participation in another interventional trial or investigational product use within 30 days prior to screening.
• Known hypersensitivity: allergy to any component of Systane PRO PF or Blink Triple Care PF.
• Confounding systemic conditions: systemic diseases or medications that, in the investigator's judgment, could significantly affect tear production or ocular surface health (e.g., uncontrolled autoimmune disease, recent initiation/change of systemic medications known to affect tear production within 30 days).
• Severe visual impairment in the study eye(s) not attributable to DED that would interfere with assessments.
• Pregnancy or breastfeeding.
• Investigator discretion: any medical, psychiatric, or social condition that would preclude safe participation or reliable completion of study procedures.

Where it is running

• Gordon Schanzlin New Vision Institute — La Jolla, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.